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Myelo-cytotoxicity of extended nitrous oxide (N,O) inhalation was described almost forty 
years ago and then incidentally applied already with temporary success for suppressing 
leukemia. In 1948 the accompanying megaloblastic maturation arrest was explained by 
inactivation of the methylcobalamin coenzyme and subsequent folate deficiency. We 
studied the anti-leukemic effect of N,O on a transplantable acute leukemia in B(rown) 
N(orway) rats. Progression of this B,N,M(yelocytic)L(eukemia) was measured as spleen 
and liver weights, and leukemic blood cell counts. The deoxyuridine (dU)-suppression 
test provided in vitro indication of the functional folate activity of leukemic cells. Breath- 
ing of N,O-oxygen considerably reduced but did not eradicate, BNML-proliferation. Ad- 
dition of anti-metabolites, interfering with some enzyme in the folate metabolism beyond 
the methylcobalamin co-enzyme dependent methionine synthase step, acted at least 
synergistically. The anti-leukemic effect of cycloleucine, which reduces S-adenosyl-me- 
thionine synthesis by inactivation of methionine adenosyltransferase, was moderate but 
became much stronger with N,O inhalation. Methotrexate, a potent anti-leukemic agent 
by inhibiting tetrahydrofolate (THF) generation through inactivation of di-HF reductase, 
became highly anti-BNML, even in low dosage when combined with or preceded by N,O. 
5-Fluorouracil, which inhibits methylene-THF dependent thymidilate synthase, itself was 
surprisingly anti-BNML, but also became much more potent with previous or concomit- 
tant N,O exposure. Preliminary dU-suppression test results with human acute leukemia 
cells, exposed to N,O and/or folate antagonists in vitro, correlated well with the in vivo 
BNML-experiments. Combining the anticobalamin activity of N,O with an anti-folate 
therefore seems to be a promising chemotherapeutic approach. 
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Inhalation of nitrous oxide (N20)  has been known for 
almost two centuries to have an anesthetic effect [ I ] .  It is 
still widely utilised as an adjuvant in present day anes- 
thesiology. Regarded to be an inert and non-toxic gas for 
a long time, on the contrary it appeared to cause severe 
anemia when inhaled for 2 weeks or more by curare- 
paralyzed patients with tetanus, who were tranquilized 
with N,O during artificial respiration [2]. This myelo- 
suppressive effect of N,O inspired its opportunistic use 
in the treatment of hyperleukocytosis in two cases of 
both chronic myeloid leukemia [ 3 ]  and childhood acute 
myeloid leukemia 141 with spectacular, but short-term, 
remissions. Cytotoxicity of N,O has also been reported 
for cultured embryonal mouse cells [ 5 ] ,  hematopoiesis in 
rodents [S], fibrosarcoma in mice [7], and Ehrlich ascites 
tumor 181. This side effect of N,O became elucidated 
when its chemical reactivity with metal complexes, by 
which it induces the conversion of cob(1)alamin to co- 
b(II)alamin, was discovered [9]. The clinical implication 
of this oxidative reaction with methylcobalamin was rec- 
ognized 10 years later to be the cause of megaloblastic 
hematopoiesis occurring after long-term N,O anesthesia 
[lo]. Deoxyuridine (dU) suppression tests on bone mar- 
row cells megaloblastically transformed by N,O ren- 
dered the same results as on those in florid pernicious 
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Fig. 1. Enzymatic steps in the cobalarnin-folate rnetabo- 
lisrn, which can be inhibited selectively. Abbreviations: rne- 
B,, = rnethylcobalarnin; SAM = S-adenosylrnethionine; 
THF = tetrahydro-folate; DHF = dihydrofolate; dUMP = 
deoxyuridinernonophosphate; dTMP = deoxythyrnidine- 
rnonophosphate. 
anemia. Thus, it became apparent that N 2 0  impairs 
DNA-synthesis through inactivation of the cob(1)alamin- 
dependent enzyme methionine synthase, which catalyzes 
the methylation of homocysteine in the generation of 
methionine under simultaneous demethylation of methyl- 
tetrahydrofolate to tetrahydrofolate (THF) (Fig. 1). De- 
ficiency and inactivation of methylcobalamin both lead 
to a functional deficiency of folates by the “trapping” of 
metabolically formed methyl-THF and by the decreased 
potential of utilizing plasma folate, which is transported 
as methyl-THF after intestinal absorption [l l-131. N,O 
may provoke subacute combined degeneration of the spi- 
nal cord in vitamin B,-deficient subjects [ 141. Analogous 
neurological complications have followed interrupted 
N,O breathing in addicted dentists [15] and continuous 
exposure in cynomolgus monkeys [ 161. 
The cobalamin-dependent methionine synthase reac- 
tion is also active in malignant hematopoietic cells [17- 
191, and cobalamin deficiency has been reported to in- 
hibit cell proliferation in chronic [20] and acute myeloid 
leukemia [2 11. The functional methyl-cobalamin defi- 
ciency induced by N,O seems to be strategically targeted 
at the enzymatic activity of methionine synthase [22]. 
The following is a review of our studies on the che- 
motherapeutic potential of N,O, alone or in combination 
with other anti-folates, in an experimental acute leuke- 
was originally provoked by benzanthracene in a Brown 
Norway (BN) rat [32] and called BNM(yeloid)L(euke- 
mia). This BNML, resembling human acute promyelo- 
cytic leukemia [33], is transplanted by intraperitoneal 
injection with lo7 cells extracted from a leukemic spleen. 
Death ensues predictably 20-24 days later from throm- 
bocytopenia, when proliferation of the leukemia has pro- 
gressed to pronounced splenomegaly, hepatomegaly, 
and peripheral promyelocytosis. These parameters, 
which reliably reflect progression of the leukemia, were 
usually determined at the 19th or 20th day after inocu- 
lation. Under N,O treatment, consisting of exposition to 
a continuous flow of 50% N,O-50% 0, in a closed 
system, the rats remained awake and able to eat and 
drink sufficiently. N,O from day 8-18 after leukemia 
transplantation caused retardation of leukemic prolifera- 
tion, as spleen and liver weights became 30% lower than 
in untreated animals, and blood promyelocytes were con- 
siderably reduced. Increase in plasma cobalamin, which 
runs parallel with leukemic expansion, regressed during 
N20 exposure, whereas plasma folate, which remains 
stable in leukemic rats, almost doubled during N,O ex- 
posure, probably reflecting methylfolate trapping. The 
dU-suppression test on leukemic spleen cells from N,O 
treated rats showed decrease of “de novo” thymidine 
synthesis in comparison with non-treated rats, compati- 
ble with methylcobalamin inactivation [34]. The overall 
results in BNML rats indicate that continuous breathing 
of N,O retards leukemic growth but does not eradicate 
the leukemic process [23,28]. Possible synergism of 
N,O with other folate antagonists, known to interfere 
with specific enzymatic steps in the folate metabolism 
(Fig. I ) ,  was also explored. Cycloleucine in lower dos- 
age is a fairly weak cytostatic agent, but in higher dosage 
develops limiting neurological and hematological toxic- 
ity [35 -371. It inhibits the methionine adenosyltrans- 
ferase-dependent generation of S-adenosylmethionine 
(SAM), which is a basic substrate for vital methylation 
reactions, synthesis of polyamines, and endogenous for- 
mation of methionine. SAM also has been found to be an 
allosteric inhibitor of methylene-THF reductase. Lower- 
ing of SAM therefore will promote the trapping of 
methyl-THF, when demethylation has been blocked by 
N20. Cycloleucine, 50 mg/kg injected i.p. in BNML- 
rats at leukemia day 7, reduced spleen and liver weights 
at day 20 to almost the same degree as did continuous 
inhalation of N 2 0  from day 7 to 19. Combination of the 
two treatments was clearly synergistic as evidenced by 
further lowering of liver and spleen weights, and by a 
drop in peripheral leukemic cell counts. dU-suppression 
tests on leukemic spleen cells 24 hours after injecting 
cycloleucine and/or starting N,O inhalation showed little 
change after separate exposures but considerably more in 
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cornbination. It made no difference if cycloleucine was 
injected or added in vitro to spleen cells from N,O- 
treated leukemic rats [24]. 
Methotrexate (MTX), the inhibitor of di-hydrofolate 
(DHF) reductase, which is crucial for the maintenance of 
intracellular THF pools, has since long been widely ap- 
plied in the treatment of acute leukemias, lymphomas, 
and solid tumors [38]. Its dose-limiting toxicity has more 
recently been combatted with so-called folinic acid (leu- 
kovorin) rescue, a MTX antidote, after high-dose MTX. 
Synergism between N 2 0  and MTX has been suggested to 
be the explanation for unexpected toxicity of adjuvant 
chemotherapy containing MTX, shortly after anesthesia 
with N,O during surgery for breast carcinoma [39]. In 
BNML rats, sacrificed on the 20th day of leukemia, 2 
mg/kg MTX i.p. on day 10, was less effective than N 2 0  
from day 7 to 19, but when MTX was preceded by 3 days 
(7- 10) N,O, reduction of hepatosplenomegaly and leu- 
kocytosis was larger than with only continuous N,O (day 
7-19); the latter combined with 2 mgikg MTX i.p. at day 
10 still further enforced the anti-leukemic effect. Dou- 
bling of the MTX dose to 4 mgikg made it equivalent to 
continuous N,O; when it was preceded by 3 days N,O, 
a very strong leukemia regression was seen, whereas in 
combination with continuous N,O the rats died from 
toxic effects at day 12-14 without obvious leukemia. 
Reductions in peripheral promelocytes ran parallel with 
decreasing spleen weights as well as plasma cobalamin 
levels, which doubled in untreated animals and dropped 
to subnormal in the most effective combined treatments. 
dU-suppression test values on leukemic spleen cells, 18 
hours after MTX i.p. 0,5 mg/kg, increased in parallel 
with previous exposure to N,O for 1 ,  2, or 3 days, 
whereas intracellular d-TTP decreased 1251. Surprisingly 
synergism did not occur when N,O was administered 
after MTX. 
Another antifolate, 5-fluorouracil (FU), which con>- 
petitively inhibits thymidylate synthase, has for long 
been a valuable ingredient in chemotherapy of especially 
breast and bowel carcinomas [40,4 I], but has usually 
been regarded to be of little value in the treatment of 
leukemias. Application of FU in BNML rats showed that 
this anti-folate itself already has a striking anti-leukemic 
potency when evaluated on leukemia day 20. A low dose 
of 3 X 15 mgikg FU i.p. on days 7 ,  12, and 17 was as 
effective as N,O on days 7-19, and combination of the 
two was shown to be synergistic. After a single dose of 
25 ingikg FU i.p. on day 14, liver and spleen weights had 
only slightly increased at sacrifice, and when preceded 
by 4 days inhalation of N,O these weights even remained 
normal with disappearance of leukemic cells in the pe- 
ripheral blood. As with MTX, synergism was absent 
when N,O was inhaled after injection of FU. BNML rat 
survival, being 22.0 ? 0.5 days, increased to 34.3 5 
0.5 days with 25 mg/kg FU on day 14 and even to 40.2 
i 1.5 days with additional N,O at days 10-14. The 
anti-leukemic effect of FU was also mirrored by increas- 
ing dU suppression test values and decreasing intracel- 
lular folate levels [26,29]. 
The studies in BNML rats in general indicate that N,O 
has a moderate anti-leukemic effect when breathed con- 
tinuously. Its methyl-cobalamin inactivation in the rats 
has probably been maximal with continuous inhalation of 
50% N,0/50% 0,. In man the cytotoxic effect of N 2 0  
may be relatively stronger in view of the reported acci- 
dental and intended cytopenias [2-41. Recently a dra- 
matic reduction of hyper-Ieukocytosis during 4 days of 
N,O in a patient with chronic myelogenous leukemia was 
reported [42]. I t  is possible that the same antileukemic 
effect can be obtained with intermittent inhalation or 
with lower concentrations of N,O 143,441, which would 
make the application in clinical practice more accept- 
able. N 2 0  inhalation seems to be an attractive alternative 
for, or an adjunct to, leukapheresis or high-dose hydroxy- 
carbamide in the treatment of hyperleukocytosis. Its role 
in the treatment of acute leukemias has to be sought in 
the synergism with other anti-folates, as a basis on which 
cycloleucine, and especially MTX and FU, become ef- 
fective in smaller and therefore probably less toxic dos- 
ages. In the BNML rats the ratio of effectiveness and 
toxicity of antifolates seems to become more favorable in 
combination with N20.  Studies on MTX toxicity in nor- 
mal rats are showing that the LD,, falls from 60 mgikg 
to 10 mgikg after exposure to N,O for 48 hours; 5- 
formyl-THF remains a good antidote, but methyl-THF is 
not, in agreement with the expected outcome [30]. The 
anti-leukemic property of FU in BNML rats is surprising 
in view of its impopularity in the treatment of human 
acute leukemias [31]. FU in combination with MTX is 
being used in chemotherapy of solid tumors and recently 
has been reported to induce complete remissions in some 
patients with refractory leukemia [45]. We have found 
that dU-suppression test values on bone marrow cells 
from 18 patients with acute leukemia change moderately 
after in vitro exposure to N,O but increase significantly 
with addition of cycloleucine, MTX, or FU, in concor- 
dance with the synergism observed in BNML rats [29]. 
This possibly predicts that combining anti-folates with 
N,O might render an attractive approach in the treatment 
of acute leukemias. 
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